MiMedx (NSDQ:MDXG) said today that it filed an IND with the FDA for a Phase II trial of its AmnioFix product in patients with osteoarthritis of the knee.
The 318-patient study is designed to compare the safety and efficacy of MiMedx’s micronized dehydrated human amnion/chorion membrane (dHACM) injection with a 0.9% sodium chloride USP placebo injection.
Get the full story at our sister site, Drug Delivery Business News.
The post MiMedx files IND for Ph2 AmnioFix osteoarthritis trial appeared first on MassDevice.
from MassDevice http://ift.tt/2fgSBhx
Cap comentari:
Publica un comentari a l'entrada